The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst
: Umang, in your annual report, there's a comment about -- and I think you've mentioned this several times in the past, about calibrating your U.S.
investment. As we now reset our base of this year with ProAir, do you think it makes sense to broad base our launch pipeline like some of our peers
have done to capture increasing share that comes out of the existing product portfolio?
Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst
: Sure. So in your annual report, there's a mention about calibrating your U.S. investment. Now that we are resetting our U.S. sales with Albuterol,
do you see the need of sort of broadening your launch pipeline for next year, having more number of launches other than the differentiated
launches to continue double-digit growth in the U.S.?
Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst
: Yes. Okay. Understood. My second question is on the One-India strategy. Earlier this week, there was news about a fair bit of churn in your India
management. Does this impact the strategy that you will see for India? Would you like to comment on that?
Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst
: Understood. And if I may squeeze in one more for India. In the trade generic business, have we gone back to our pre reorganization efforts that
we had last year? Have sales recovered to that level?
Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst
: Sir, 2 things. One is, a, on the emerging markets. You mentioned about some more biosimilars being licensed. Now how are you seeing this over
next, say, 3 to 5-year view, how do you see itself place in this whole emerging market biologics opportunity? Given the strategy that you've adopted?
Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst
: Umang, how do you see the market in the -- for some of these larger opportunities in some of these larger markets? Is it, I mean, is it going to be
actually -- I mean, with -- so a, one, a, as these kind of partnering opportunity is really available on the top literally for multiplayers to sort of
participate in these opportunities? Or are these going to remain like limited combination products across markets?
Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst
: Got it. And secondly, on this API business. There has been a lot of momentum that you've seen across most of your peer set on their API business
and people sort of recalibrating their API plans to double back or double down their business. How are we perceiving -- how -- I mean, what is our
strategy towards this business going forward from a third-party supply perspective?
| 
